Increased frequency of bronchiolar histotypes in lung carcinomas associated with idiopathic pulmonary fibrosis

Caliò, Anna; Lever, Veronica; Rossi, Andrea; Gilioli, Eliana; Brunelli, Matteo; Dubini, Alessandra; Tomassetti, Sara; Piciucchi, Sara; Nottegar, Alessia; Rossi, Giulio; Kambouchner, Marianne; Cancellieri, Alessandra; Barbareschi, Mattia; Pelosi, Giuseppe; Doglioni, Claudio; Cavazza, Alberto; Carella, Rodolfo; Graziano, Paolo; Murer, Bruno; Poletti, Venerino; Chilosi, Marco

doi:10.1111/his.13269

Cited by 33 publications

(36 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the current model of disease pathogenesis, the bronchiolization and honeycomb cysts formation occur after the formation of myofibroblast foci. ABCs are recruited potentially in response to alveolar epithelial cell injury, and their proliferation and invasion determine the distortion of the alveolar structure that we typically associate with IPF and cough [47][48][49][50]. A very recent genetic manuscript reports an unexpected finding: genes from ABCs are highly enriched in the BAL of IPF patients likely to progress, and may suggest an unexpected role of ABCs in the pathogenesis of IPF and cough [49].…”

Section: The Potential Role Of Airway Basal Cellsmentioning

confidence: 97%

“…Another intriguing aspect is the potential role of airway basal cells in IPF pathogenesis and cough development. Chilosi and coauthors report an aberrant bronchiolization in IPF lung with ∆NP63 expressing cells [47,48]. IPF animal models reveal that airway basal cells may have a potential role in the early response to fibrosis, and bronchoalveolar subpopulations of ABCs are abundantly present in fibrotic lesions [49].…”

Section: The Potential Role Of Airway Basal Cellsmentioning

confidence: 98%

See 1 more Smart Citation

The pathogenetic mechanisms of cough in idiopathic pulmonary fibrosis

et al. 2018

View full text Add to dashboard Cite

Idiopathic pulmonary fibrosis is a peripheral subpleural interstitial lung disorder limited to the lung not involving the airways. It has a poor prognosis (survival less than 5 years) and commonly an interstitial pneumonia radiological pattern. Patients complain of a chronic dry cough in 80% of cases. A cough is often the first symptom of this rare disease, preceding dyspnea by years, and is associated with a poor prognosis, high dyspnea scores and low FVC percentages. The pathogenetic mechanisms leading to coughing in IPF are unclear. This review focuses on recent evidence of cough pathophysiology in this disease. Gastroesophageal reflux may promote coughing in IPF patients; bile salts and pepsin may be abundant in BAL of these patients, inducing overproduction of TGF-β by airway epithelial cells and mesenchymal transition with fibroblast recruitment/activation and extracellular matrix deposition. Patients have an enhanced cough reflex to capsaicin and substance P with respect to control subjects. Moreover, patients with the MUC5B polymorphism show more severe coughing as MUC5B encodes for the dominant mucin in the honeycomb cysts of IPF patients. Comorbidities, including asthma, gastroesophageal reflux, hypersensitivity pneumonitis, bronchiectasis, chronic obstructive pulmonary disease and emphysema, can induce coughing in IPF patients. There is no clear explanation of the causes of coughing in IPF. Further research into the pathophysiology of IPF and the pathogenetic mechanisms of coughing is necessary to improve survival and quality of life.

show abstract

Section: The Potential Role Of Airway Basal Cellsmentioning

confidence: 97%

Section: The Potential Role Of Airway Basal Cellsmentioning

confidence: 98%

The pathogenetic mechanisms of cough in idiopathic pulmonary fibrosis

et al. 2018

View full text Add to dashboard Cite

show abstract

“…The aforementioned fibrotic/non-fibrotic border, as well as the honeycomb areas showed a topographical association with cancer [26]. Likewise, studies using the radiological examination report a peripheral lung cancer location, adjacent to areas with the radiological UIP pattern [16,33,41]. The involvement of lower lobes is significantly more frequent in the neoplastic process connected with IPF than in patients without IPF [42].…”

Section: Histopathologymentioning

confidence: 96%

Idiopathic Pulmonary Fibrosis Coexisting with Lung Cancer

Zieliński

Sitek

2018

Advances in Respiratory Medicine

View full text Add to dashboard Cite

Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease with poor prognosis. Although the underlying mechanisms are not fully understood, IPF is connected with lung cancer development, which farther worsens the prognosis. Various papers report IPF and cancer coexistence in 9.8% to over 50% of patients depending on observation period. Contrary to already established guidelines in the general population, there are no widely accepted recommendations on lung cancer treatment in IPF population. At the same time, various oncologic interventions can result in acute exacerbation of IPF. In this paper authors tried to revise the available data on lung cancer in patients with preexisting IPF.

show abstract

“…Other interesting studies describe the histotypes and the morphological and molecular features of lung cancer in patients with pulmonary fibrosis: in contrast with previous studies, they report a higher percentage of adenocarcinoma in cases with fibrosis having certain molecular features [5]. Another article described the frequency of EGFR mutation, ALK and ROS1 rearrangement and PDL 1 expression in patients with fibrosis and lung cancer [19][20][21].…”

Section: Casementioning

confidence: 96%

“…The panorama of treatment options includes new immunotherapeutic drugs, approved for lung cancer therapy. These molecules enhance anti-tumor immunity by inhibiting negative T cell regulators and programmed cell-death-1 [4][5][6][7][8][9][10]. Immune checkpoint inhibitors currently approved for treatment of advanced NSCLC include nivolumab (anti CTLA-4 and anti PD1), pembrolizumab (anti PD1) and atezolizumab (anti PDL-1) [7,8].…”

Section: Introductionmentioning

confidence: 99%

Fibrotic lung toxicity induced by cytotoxic drugs, radiation and immunotherapy in patients treated for lung cancer

Bargagli¹,

Bonti²,

Bindi

et al. 2018

Monaldi Arch Chest Dis

View full text Add to dashboard Cite

Patients treated for lung cancer may develop lung toxicity induced by chemotherapy (DILD), radiation or combined radiation recall pneumonitis. In the literature, some cases of immune-mediated pneumonitis have been reported associated with immunotherapy. The clinical and radiologic features of interstitial lung toxicity are unspecific, dyspnea and dry cough are the most common symptoms while the most frequent radiological pattern is the cryptogenic organizing pneumonia (COP). Why only some individuals treated with these drugs develop interstitial lung toxicity is unclear. Old age, ethnicity, doses, drug interactions, oxygen damage and radiation therapy are known risk factors, as well as pre-existing lung disease. There are no clear indicators of the risk of developing lung toxicity secondary to drugs or radiation for individual patients. In the last few years some studies have reported the utility of KL 6 for the evaluation of DILD. The treatment is based on high doses of systemic steroids or immune suppressor. In this study we report severe interstitial lung damage in patients treated with different anti-blastic, immune and radiation therapies. Treated with surgery, chemotherapy, immuno-and radiotherapy for lung cancer, they unfortunately died of severe DILD.

show abstract

Increased frequency of bronchiolar histotypes in lung carcinomas associated with idiopathic pulmonary fibrosis

Cited by 33 publications

References 54 publications

The pathogenetic mechanisms of cough in idiopathic pulmonary fibrosis

The pathogenetic mechanisms of cough in idiopathic pulmonary fibrosis

Idiopathic Pulmonary Fibrosis Coexisting with Lung Cancer

Fibrotic lung toxicity induced by cytotoxic drugs, radiation and immunotherapy in patients treated for lung cancer

Contact Info

Product

Resources

About